<h4>Introduction</h4>Berotralstat, the first oral plasma kallikrein inhibitor approved for hereditary angioedema (HAE) prophylaxis, may be associated with gastrointestinal (GI) side effects, particularly during the first three months of therapy. This evidence concerns the gene KLK4 and hereditary angioedema.